Structure-activity relationship studies on clinically relevant HIV-1 NNRTIs

Current Medicinal Chemistry

Volumn 19, Issue 31, 2012, Pages 5364-5380

  Rawal, R K ^a,b   Murugesan, V ^a   Katti, S B ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

AIDS; Delavirdine; DNA; Efavirenz; Etravirine; HIV; Nevirapine; NNRTIs; NRTIs; PIs; Rilpivirine; RNA

Indexed keywords

2 BENZYL 4 CYANOMETHYLENE 1,1,3 TRIOXO 2H,4H THIENO[3,4 E][1,2,4]THIADIAZINE; 3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; 4 THIAZOLIDINONE DERIVATIVE; ABACAVIR; AMINO ACID; AMPRENAVIR; ATAZANAVIR; DAPIVIRINE; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NELFINAVIR; NEVIRAPINE; NSC 287474; NSC 625487; PNU 14272; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; TIVIRAPINE; TROVIRDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; BINDING SITE; CD4+ T LYMPHOCYTE; DRUG BINDING SITE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIFE CYCLE; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS STRAIN;

BENZOXAZINES; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; PIPERAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TRIAZINES;

EID: 84870447919     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803833326     Document Type: Article

References (79)

1. Gallo, R., Historical essay: The early years of HIV/AIDS. Science, 2002, 298, (5599), 1728.
2. De Clercq, E., Highlights in the Discovery of Antiviral Drugs: A Personal Retrospective. J. Med. Chem., 2009, 53, (4), 1438-1450.
3. http://www.unaids.org/documents/20101123-GlobalReport-em.pdf
4. http://www.who.int/hiv/data/fast-facts/en/.
5. De Clercq, E., Novel compounds in preclinical/early clinical development for the treatment of HIV infections. Rev. Med. Virol., 2000, 10, (4), 255-277.
6. De Clercq, E., The design of drugs for HIV and HCV. Nat. Rev. Drug Discov., 2007, 6, (12), 1001-1018.
7. Turner, B.G.; Summers, M.F., Structural biology of HIV. J. Mol. Biol., 1999, 285, (1), 1-32.
8. Esté, J.A.; Cihlar, T., Current status and challenges of antiretroviral research and therapy. Antiviral Res. 2010, 85, (1), 25-33.
9. Kohlstaedt, L.; Wang, J.; Friedman, J.; Rice, P.; Steitz, T., Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science, 1992, 256, (5065), 1783.
10. Smith, R.H.; J. Michejda, C.; Hughes, S.H.; Arnold, E.; Janssen, P.A.J.; Kroeger Smith, M.B., Structure and mechanism of action of nonnucleoside inhibitors of HIV-1 reverse transcriptase: strategies to combat drug resistance. J. Mol. Stru.: THEOCHEM, 1998, 423, (1-2), 67-77.
11. De Clercq, E., New Approaches toward Anti-HIV Chemotherapy. J. Med. Chem., 2005, 48, (5), 1297-1313.
12. Alcaro, S.; Alteri, C.; Artese, A.; Ceccherini-Silberstein, F.; Costa, G.; Ortuso, F.; Parrotta, L.; Perno, C.F.; Svicher, V., Molecular and structural aspects of clinically relevant mutations related to the approved nonnucleoside inhibitors of HIV-1 reverse transcriptase. Drug Resist. Updates, 2011, 14, (3), 141-149.
13. Menéndez-Arias, L., Molecular basis of human immunodeficiency virus drug resistance: An update. Antiviral Res., 2010, 85, (1), 210-231.
14. Ren, J.; Stammers, D.K., Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res., 2008, 134, (1-2), 157-170.
15. Ceccherini-Silberstein, F.; Svicher, V.; Sing, T.; Artese, A.; Santoro, M.M.; Forbici, F.; Bertoli, A.; Alcaro, S.; Palamara, G.; Monforte, A.A., Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J. Virol., 2007, 81, (20), 11507-11519.
16. Alcaro, S.; Artese, A.; Ceccherini-Silberstein, F.; Chiarella, V.; Dimonte, S.; Ortuso, F.; Perno, C.F., Computational Analysis of Human Immunodeficiency Virus (HIV) Type-1 Reverse Transcriptase Crystallographic Models Based on Significant Conserved Residues Found in Highly Active Antiretroviral Therapy (HAART)-Treated Patients (Supplementary Material). Curr. Med. Chem., 2010, 17, (4), 290-308.
17. Alcaro, S.; Alteri, C.; Artese, A.; Ceccherini-Silberstein, F.; Costa, G.; Ortuso, F.; Bertoli, A.; Forbici, F.; Santoro, M.M.; Parrotta, L., Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine. ChemMedChem, 2011, 6, (12), 2203-2213.
18. Wang, X.; Zhang, J.; Huang, Y.; Wang, R.; Zhang, L.; Qiao, K.; Li, L.; Liu, C.; Ouyang, Y.; Xu, W.; Zhang, Z.; Zhang, L.; Shao, Y.; Jiang, S.; Ma, L.; Liu, J., Design, Synthesis, and Biological Evaluation of 1-[(2-Benzyloxyl/ alkoxyl)methyl]-5-halo-6-aryluracils as Potent HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with an Improved Drug Resistance Profile. J. Med. Chem, 2012, 55, (5), 2242-2250.
19. Hargrave, K.D.; Proudfoot, J.R.; Adams, J.; Grozinger, K.G.; Schmidt, G.; Engel, W.; Trummlitz, G.; Eberlein, W. 5, 11-dihydro-6H-dipyrido (3, 2-B: 2′, 3′-E)(1, 4) diazepines and their use in the prevention or treatment of HIV infection. U.S. Patent 5,366,972, November 22, 1994.
20. Martino, A.C.; Bates, A.H.; Morozowich, W.; Lee, E.J. Delavirdine high strength tablet formulation. U.S. Patent 5,563,142, Jan 23, 2001.
21. Young, S.D.; Britcher, S.F.; Payne, L.S.; Tran, L.O.; Lumma Jr, W.C. Benzoxazinones as inhibitors of HIV reverse transcriptase. U.S. Patent 5,519,021, May 21, 1996.
22. Yang, S.; Chen, F.E.; De Clercq, E., Dihydro-alkoxyl-benzyl-oxopyrimidine Derivatives (DABOs) As Non-Nucleoside Reverse Transcriptase Inhibitors: An Update Review (2001-2011). Curr. Med. Chem., 2012, 19, (2), 152-162.
23. Zhan, P.; Chen, X.; Li, D.; Fang, Z.; De Clercq, E.; Liu, X., HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design. Med. Res. Rev., 2011.
24. Zhou, T.; Shi, Q.; Chen, C.H.; Huang, L.; Ho, P.; Morris-Natschke, S.L.; Lee, K.H., Anti-AIDS agents 85. Design, synthesis, and evaluation of 1R, 2R-dicamphanoyl-3, 3-dimethyldihydropyrano-[2, 3-c] xanthen-7 (1H)-one (DCX) derivatives as novel anti-HIV agents. Eur. J. Med. Chem., 2011.
25. Jorgensen, W.L.; Bollini, M.; Thakur, V.V.; Domaoal, R.A.; Spasov, K.A.; Anderson, K.S., Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase. J. Am. Chem. Soc., 2011.
26. Gomez, R.; Jolly, S.; Williams, T.M.; Vacca, J.P.; Torrent, M.; McGaughey, G.; Lai, M.T.; felock, p.j.; Munshi, V.; DiStefano, D., Design and Synthesis of conformationally Constrained Inhibitors of Non-Nucleoside Reverse Transcriptase. J. Med. Chem., 2011.
27. Boyer, J.; Arnoult, E.; Medebielle, M.; Guillemont, J.; Unge, J.; Jochmans, D., Difluoromethylbenzoxazole pyrimidine thioether derivatives: a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem., 2011.
28. Li, D.; Zhan, P.; De Clercq, E.; Liu, X., Strategies for the Design of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Lessons from the Development of Seven Representative Paradigms. J. Med. Chem., 2012, 55, (8), 3595-3613.
29. Hargrave, K.D.; Proudfoot, J.R.; Grozinger, K.G.; Cullen, E.; Kapadia, S.R.; Patel, U.R.; Fuchs, V.U.; Mauldin, S.C.; Vitous, J., Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. J. Med. Chem., 1991, 34, (7), 2231-2241.
30. Glynn, S.; Yazdanian, M., In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J. Pharmaceut. Sci., 1998, 87, (3), 306-310.
31. Proudfoot, J.R.; Hargrave, K.D.; Kapadia, S.R.; Patel, U.R.; Grozinger, K.G.; McNeil, D.W.; Cullen, E.; Cardozo, M.; Tong, L., Novel Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase. 4. 2-Substituted Dipyridodiazepinones as Potent Inhibitors of Both Wild-Type and Cysteine-181 HIV-1 Reverse Transcriptase Enzymes. J. Med. Chem., 1995, 38, (24), 4830-4838.
32. Klunder, J.M.; Hoermann, M.; Cywin, C.L.; David, E.; Brickwood, J.R.; Schwartz, R.; Barringer, K.J.; Pauletti, D.; Shih, C.-K.; Erickson, D.A.; Sorge, C.L.; Joseph, D.P.; Hattox, S.E.; Adams, J.; Grob, P.M., Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 7. 8-Arylethyldipyridodiazepinones as Potent Broad-Spectrum Inhibitors of Wild-Type and Mutant Enzymes. J. Med. Chem., 1998, 41, (16), 2960-2971.
33. Larder, B.; DJM, P., Powell KL. and Darby G: Site-specific mutagenesis of AIDS virus reverse transcriptase. Nature, 1987, 327, 716-717.
34. Cywin, C.L.; Klunder, J.M.; Hoermann, M.; Brickwood, J.R.; David, E.; Grob, P.M.; Schwartz, R.; Pauletti, D.; Barringer, K.J.; Shih, C.-K.; Sorge, C.L.; Erickson, D.A.; Joseph, D.P.; Hattox, S.E., Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 8. 8-Aryloxymethyl- and 8- Arylthiomethyldipyridodiazepinones1. J. Med. Chem., 1998, 41, (16), 2972-2984.
35. Kelly, T.A.; McNeil, D.W.; Rose, J.M.; David, E.; Shih, C.-K.; Grob, P.M., Novel Non-Nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. 6. 2-Indol-3-yl- and 2-Azaindol-3- yldipyridodiazepinones1. J. Med. Chem., 1997, 40, (15), 2430-2433.
36. O'Meara, J.A.; Yoakim, C.; Bonneau, P.R.; Bös, M.; Cordingley, M.G.; Déziel, R.; Doyon, L.; Duan, J.; Garneau, M.; Guse, I.; Landry, S.; Malenfant, E.; Naud, J.; Ogilvie, W.W.; Thavonekham, B.; Simoneau, B., Novel 8-Substituted Dipyridodiazepinone Inhibitors with a Broad-Spectrum of Activity against HIV-1 Strains Resistant to Non-nucleoside Reverse Transcriptase Inhibitors. J. Med. Chem., 2005, 48, (17), 5580-5588.
37. Yoakim, C.; Bonneau, P.R.; Déziel, R.; Doyon, L.; Duan, J.; Guse, I.; Landry, S.; Malenfant, E.; Naud, J.; Ogilvie, W.W.; O'Meara, J.A.; Plante, R.; Simoneau, B.; Thavonekham, B.; Bös, M.; Cordingley, M.G., Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives. Bioorg. Med. Chem. Lett., 2004, 14, (3), 739-742.
38. Barth, B.; Dierich, M.; Heinisch, G.; Jenny, V.; Matuszczak, B.; MERELTER, K.; Planer, R.; Schöpf, I.; STOLBER, H.; Traugott, T., Pyridazino [3, 4-b][1, 5] benzoxazepin-5 (6H)-ones: synthesis and biological evaluation. Antiviral Chem. Chemother., 1996, 7, (6), 300-312.
39. Heinisch, G.; Huber, E.; Matuszczak, B.; Maurer, A.; Prillinger, U., Pyridazines 82 [1]. Synthesis of Pyridazino [3, 4 b][1, 5] benzodiazepin 5 ones and their Biological Evaluation as Non nucleoside HIV Reverse Transcriptase Inhibitors. Archiv der Pharm., 1997, 330, (1 2), 29-34.
40. Romero, D.; Busso, M.; Tan, C.; Reusser, F.; Palmer, J.; Poppe, S.; Aristoff, P.; Downey, K.; So, A.; Resnick, L., Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Nat. Acad. Sci. U.S.A., 1991, 88, (19), 8806.
41. Romero, D.L.; Morge, R.A.; Biles, C.; Berrios-Pena, N.; May, P.D.; Palmer, J.R.; Johnson, P.D.; Smith, H.W.; Busso, M.; et, a., Discovery, Synthesis, and Bioactivity of Bis(heteroaryl)piperazines. 1. A Novel Class of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. J. Med. Chem., 1994, 37, (7), 999-1014.
42. Romero, D.L.; Olmsted, R.A.; Poel, T.J.; Morge, R.A.; Biles, C.; Keiser, B.J.; Kopta, L.A.; Friis, J.M.; Hosley, J.D.; Stefanski, K.J.; Wishka, D.G.; Evans, D.B.; Morris, J.; Stehle, R.G.; Sharma, S.K.; Yagi, Y.; Voorman, R.L.; Adams, W.J.; Tarpley, W.G.; Thomas, R.C., Targeting Delavirdine/Atevirdine Resistant HIV-1: Identification of (Alkylamino)piperidine-Containing Bis(heteroaryl)piperazines as Broad Spectrum HIV-1 Reverse Transcriptase Inhibitors. J. Med. Chem., 1996, 39, (19), 3769-3789.
43. Dueweke, T.; Poppe, S.; Romero, D.; Swaney, S.; So, A.; Downey, K.; Althaus, I.; Reusser, F.; Busso, M.; Resnick, L., U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother., 1993, 37, (5), 1127.
44. Genin, M.J.; Poel, T.J.; May, P.D.; Kopta, L.A.; Yagi, Y.; Olmsted, R.A.; Friis, J.M.; Voorman, R.L.; Adams, W.J.; Thomas, R.C.; Romero, D.L., Synthesis and Structure-Activity Relationships of the (Alkylamino)piperidine-Containing BHAP Class of Non-Nucleoside Reverse Transcriptase Inhibitors: Effect of 3-Alkylpyridine Ring Substitution. J. Med. Chem., 1999, 42, (20), 4140-4149.
45. Young, S.; Britcher, S.; Tran, L.; Payne, L.; Lumma, W.; Lyle, T.; Huff, J.; Anderson, P.; Olsen, D.; Carroll, S., L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother., 1995, 39, (12), 2602.
46. Patel, M.; McHugh, R.J.; Cordova, B.C.; Klabe, R.M.; Erickson-Viitanen, S.; Trainor, G.L.; Ko, S.S., Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA). Bioorg. Med. Chem. Lett., 1999, 9, (22), 3221-3224.
47. Patel, M.; Ko, S.S.; McHugh, R.J.; Markwalder, J.A.; Srivastava, A.S.; Cordova, B.C.; Klabe, R.M.; Erickson-Viitanen, S.; Trainor, G.L.; Seitz, S.P., Synthesis and evaluation of analogs of Efavirenz (SUSTIVATM) as HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 1999, 9, (19), 2805-2810.
48. Cocuzza, A.J.; Chidester, D.R.; Cordova, B.C.; Jeffrey, S.; Parsons, R.L.; Bacheler, L.T.; Erickson-Viitanen, S.; Trainor, G.L.; Ko, S.S., Synthesis and Evaluation of Efavirenz (SustivaTM) Analogs as HIV-1 Reverse Transcriptase Inhibitors: Replacement of the Cyclopropylacetylene Side Chain. Bioorg. Med. Chem. Lett., 2001, 11, (9), 1177-1179.
49. Corbett, J.W.; Ko, S.S.; Rodgers, J.D.; Gearhart, L.A.; Magnus, N.A.; Bacheler, L.T.; Diamond, S.; Jeffrey, S.; Klabe, R.M.; Cordova, B.C.; Garber, S.; Logue, K.; Trainor, G.L.; Anderson, P.S.; Erickson-Viitanen, S.K., Inhibition of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors. J. Med. Chem., 2000, 43, (10), 2019-2030.
50. Udier-Blagović, M.; Tirado-Rives, J.; Jorgensen, W.L., Structural and Energetic Analyses of the Effects of the K103N Mutation of HIV-1 Reverse Transcriptase on Efavirenz Analogs. J. Med. Chem., 2004, 47, (9), 2389-2392.
51. Markwalder, J.A.; Christ, D.D.; Mutlib, A.; Cordova, B.C.; Klabe, R.M.; Seitz, S.P., Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor Efavirenz. Bioorg. Med. Chem. Lett., 2001, 11, (5), 619-622.
52. Corbett, J.; Ko, S.; Rodgers, J.; Jeffrey, S.; Bacheler, L.; Klabe, R.; Diamond, S.; Lai, C.; Rabel, S.; Saye, J., Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 1999, 43, (12), 2893.
53. De Corte, B.; De Jonge, M.R.; Heeres, J.; Ho, C.Y.; Janssen, P.A.J.; Kavash, R.W.; Koymans, L.M.H.; Kukla, M.J.; Ludovici, D.W.; Van Aken, K.J.A. HIV replication inhibiting pyrimidines. U.S. Patent 6,878,717, April 12, 2005.
54. Ludovici, D.W.; Kavash, R.W.; Kukla, M.J.; Ho, C.Y.; Ye, H.; De Corte, B.L.; Andries, K.; de Béthune, M.-P.; Azijn, H.; Pauwels, R.; Moereels, H.E.L.; Heeres, J.; Koymans, L.M.H.; de Jonge, M.R.; Van Aken, K.J.A.; Daeyaert, F.F.D.; J. Lewi, P.; Das, K.; Arnold, E.; Janssen, P.A.J., Evolution of Anti-HIV Drug CandidatesPart 2: Diaryltriazine (DATA) Analogs. Bioorg. Med. Chem. Lett., 2001, 11, (17), 2229-2234.
55. Xiong, Y.-Z.; Chen, F.-E.; Balzarini, J.; De Clercq, E.; Pannecouque, C., Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: Structural modulations of diaryltriazines with potent anti-HIV activity. Eur. J. Med. Chem., 2008, 43, (6), 1230-1236.
56. Xiong, Y.Z.; Chen, F.E.; Balzarini, J.; De Clercq, E.; Pannecouque, C., Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. Part 13. Chem. Biodivers., 2009, 6, (4), 561-568.
57. Ludovici, D.W.; De Corte, B.L.; Kukla, M.J.; Ye, H.; Ho, C.Y.; Lichtenstein, M.A.; Kavash, R.W.; Andries, K.; de Béthune, M.-P.; Azijn, H.; Pauwels, R.; Lewi, P.J.; Heeres, J.; Koymans, L.M.H.; de Jonge, M.R.; Van Aken, K.J.A.; Daeyaert, F.F.D.; Das, K.; Arnold, E.; Janssen, P.A.J., Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogs. Bioorg. Med. Chem. Lett., 2001, 11, (17), 2235-2239.
58. Das, K.; Clark, A.D.; Lewi, P.J.; Heeres, J.; de Jonge, M.R.; Koymans, L.M.H.; Vinkers, H.M.; Daeyaert, F.; Ludovici, D.W.; Kukla, M.J.; De Corte, B.; Kavash, R.W.; Ho, C.Y.; Ye, H.; Lichtenstein, M.A.; Andries, K.; Pauwels, R.; de Béthune, M.-P.; Boyer, P.L.; Clark, P.; Hughes, S.H.; Janssen, P.A.J.; Arnold, E., Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 Variants. J. Med. Chem., 2004, 47, (10), 2550-2560.
59. Janssen, P.A.J.; Lewi, P.J.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E.; Kukla, M.; Ludovici, D.; Andries, K.; de Béthune, M.-P.; Pauwels, R.; Das, K.; Clark, A.D.; Frenkel, Y.V.; Hughes, S.H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.; Williams, P.; Stoffels, P., In Search of a Novel Anti-HIV Drug: Multidisciplinary Coordination in the Discovery of 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile (R278474, Rilpivirine). J. Med. Chem., 2005, 48, (6), 1901-1909.
60. Mordant, C.; Schmitt, B.; Pasquier, E.; Demestre, C.; Queguiner, L.; Masungi, C.; Peeters, A.; Smeulders, L.; Bettens, E.; Hertogs, K.; Heeres, J.; Lewi, P.; Guillemont, J., Synthesis of novel diarylpyrimidine analogs of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains. Eur. J. Med. Chem., 2007, 42, (5), 567-579.
61. Liang, Y.-H.; He, Q.-Q.; Zeng, Z.-S.; Liu, Z.-Q.; Feng, X.-Q.; Chen, F.-E.; Balzarini, J.; Pannecouque, C.; Clercq, E.D., Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogs as non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem., 2010, 18, (13), 4601-4605.
62. Feng, X.-Q.; Zeng, Z.-S.; Liang, Y.-H.; Chen, F.-E.; Pannecouque, C.; Balzarini, J.; Clercq, E.D., Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogs as potential nonnucleoside reverse transcriptase inhibitors against HIV. Bioorg. Med. Chem., 2010, 18, (7), 2370-2374.
63. Zeng, Z.-S.; He, Q.-Q.; Liang, Y.-H.; Feng, X.-Q.; Chen, F.-E.; Clercq, E.D.; Balzarini, J.; Pannecouque, C., Hybrid diarylbenzopyrimidine nonnucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy. Bioorg. Med. Chem., 2010, 18, (14), 5039-5047.
64. Tian, X.; Qin, B.; Lu, H.; Lai, W.; Jiang, S.; Lee, K.-H.; Chen, C.H.; Xie, L., Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, (18), 5482-5485.
65. Qin, B.; Jiang, X.; Lu, H.; Tian, X.; Barbault, F.; Huang, L.; Qian, K.; Chen, C.-H.; Huang, R.; Jiang, S.; Lee, K.-H.; Xie, L., Diarylaniline Derivatives as a Distinct Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. J. Med. Chem., 2010, 53, (13), 4906-4916.
66. Barreca, M.L.; Balzarini, J.; Chimirri, A.; Clercq, E.D.; Luca, L.D.; Höltje, H.D.; Höltje, M.; Monforte, A.M.; Monforte, P.; Pannecouque, C.; Rao, A.; Zappalà, M., Design, Synthesis, Structure-Activity Relationships, and Molecular Modeling Studies of 2,3-Diaryl-1,3-thiazolidin-4- ones as Potent Anti-HIV Agents. J. Med. Chem., 2002, 45, (24), 5410-5413.
67. Barreca, M.L.; Chimirri, A.; De Luca, L.; Monforte, A.-M.; Monforte, P.; Rao, A.; Zappalà, M.; Balzarini, J.; De Clercq, E.; Pannecouque, C.; Witvrouw, M., Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg. Med. Chem. Lett., 2001, 11, (13), 1793-1796.
68. Rawal, R.K.; Tripathi, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E., Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin- 4-one analogs as anti-HIV-1 agents. Bioorg. Med. Chem., 2007, 15, (9), 3134-3142.
69. Rawal, R.K.; Prabhakar, Y.S.; Katti, S.B.; De Clercq, E., 2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT inhibitors. Bioorg. Med. Chem., 2005, 13, (24), 6771-6776.
70. Rawal, R.K.; Tripathi, R.; Kulkarni, S.; Paranjape, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E., 2-(2,6-Dihalo-phenyl)-3-heteroaryl-2-ylmethyl-1, 3-thiazolidin-4-ones: anti-HIV agents. Chem. Biol. Drug Des., 2008, 72, (2), 147-154.
71. Rawal, R.K.; Tripathi, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E., Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Bioorg. Med. Chem., 2007, 15, (4), 1725-1731.
72. Rawal, R.K.; Tripathi, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E., Synthesis and biological evaluation of 2,3-diaryl substituted-1,3-thiazolidin-4- ones as anti-HIV agents. Med. Chem., 2007, 3, (4), 355-363.
73. Rao, A.; Balzarini, J.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monforte, P.; Pannecouque, C.; Zappalà, M., 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Antiviral Res., 2004, 63, (2), 79-84.
74. Rawal, R.K.; Tripathi, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E., Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4- ones as anti-HIV agents. Eur. J. Med. Chem., 2008, 43, (12), 2800-2806.
75. Balzarini, J.; Orzeszko, B.; Maurin, J.K.; Orzeszko, A., Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4-ones. Eur. J. Med. Chem., 2007, 42, (7), 993-1003.
76. Prabhakar, Y.S.; Rawal, R.K.; Gupta, M.K.; Solomon, V.R.; Katti, S.B., Topological descriptors in modeling the HIV inhibitory activity of 2-aryl-3-pyridyl-thiazolidin-4-ones. Comb. Chem. High Throughput Scr., 2005, 8, (5), 431-437.
77. Prabhakar, Y.S.; Solomon, V.R.; Rawal, R.K.; Gupta, M.K.; Katti, S.B., CPMLR/ PLS Directed Structure-Activity Modeling of the HIV-1 RT Inhibitory Activity of 2,3-Diaryl-1,3-thiazolidin-4-ones. QSAR & Comb. Sci., 2004, 23, (4), 234-244.
78. Rawal, R.K.; Prabhakar, Y.S.; Katti, S.B., Molecular Surface Features in Modeling the HIV-1 RT Inhibitory Activity of 2-(2, 6-Disubstituted phenyl)-3-(substituted pyrimidin-2-yl)-thiazolidin-4-ones. QSAR & Comb. Sci., 2007, 26, (3), 398-406.
79. Distinto, S.; Esposito, F.; Kirchmair, J.; Cardia, M.C.; Gaspari, M.; Maccioni, E.; Alcaro, S.; Markt, P.; Wolber, G.; Zinzula, L.; Tramontano, E., Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach. Eur. J. Med. Chem., 2012, 50, (0), 216-229.